The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  • Email Email
  • Glossary Glossary


Oct 23, 2002

How come we don't hear much about FTC? Whenever you guys discuss new treatments or once-daily options, FTC isn't mentioned.

When is it going to be approved? What do you see its place being in treatment?

tx in advance.

Response from Dr. Wohl

AS you mention, FTC is not yet approved for use so it is difficult at this time to advocate for its use as a treatment option. The drug has been under study for a long time and has hit some speed bumps along the way. Hopefully, the drug can proceed toward approval but I do not know for sure that this will happen any time very soon.

What may turn out to be a big niche for this once a day 3TC-like drug is if it is co-formulated with other HIV drugs to create a nice combination pill (a la Combivir and Trizivir). A tenofovir/FTC combination pill would be a nifty thing to have around, no? One pill once a day, two drugs. The possibilities are (almost) endless. DW

3 combinations to live?
Baseline Test: CD4 805, Viral Load 13,883

  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint